SCHEMBL4184573

SCHEMBL4184573

O=C(O)c1ccc(-c2ncc(Cl)cc2Cl)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.56
CASP1 P29466 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
XDH P47989 1/20 0.46
CNR2 P34972 1/20 0.43
DHODH Q02127 1/20 0.42
HPGD P15428 1/20 0.42
PPARG P37231 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
KMO O15229 5/20 0.41
ADH5 P11766 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PTGS2 P35354 1/20 0.40
SRD5A2 P31213 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191067 0.87 DHODH (0.47) TSHRCASP1SMN1; SMN2XDHCNR2
SCHEMBL4181900 0.81 SORT1 (0.53) SMN1; SMN2HPGDALDH1A1PDK2
SCHEMBL4186527 0.81 ADH5 (0.58) TSHRSMN1; SMN2CNR2ADH5SRD5A2
SCHEMBL4179499 0.78 KDM4E (0.51) TSHRCASP1SMN1; SMN2XDHKMO
SCHEMBL5111947 0.78 ALDH1A1 (0.56) SMN1; SMN2XDHDHODHHPGDKMO
SCHEMBL2770320 0.77 TSHR (0.68) TSHRCASP1SMN1; SMN2XDHKMO
SCHEMBL4186860 0.75 TSHR (0.44) TSHRCASP1SMN1; SMN2DHODHHPGD
SCHEMBL3417670 0.74 TSHR (0.70) TSHRCASP1SMN1; SMN2XDHHPGD
SCHEMBL9362233 0.73 GUSB (0.51) TSHRCNR2
SCHEMBL111279 0.73 TSHR (1.00) TSHRCASP1SMN1; SMN2PPARGCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
CN-101128452-B Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA 2012-11-21 CN disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
CN-101128452-A Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA (KR) 2008-02-20 CN disclosed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP disclosed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 TSHR 2576/4885CASP1 848/4885SMN1; SMN2 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.